Browsing by author "Gerlinger, Marco"
Now showing items 21-28 of 28
-
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.
Woolston, A; Barber, LJ; Griffiths, B; Pich, O; Lopez-Bigas, N; et al. (NATURE PORTFOLIO, 2021-05-20)Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRCs), but acquired resistance invariably evolves. It is unknown which mutational mechanisms enable resistance evolution and ... -
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner, FA; Winter, S; Stühler, V; Rausch, S; Hennenlotter, J; et al. (BMC, 2022-09-15)BACKGROUND: Renal cell carcinoma (RCC) is a heterogeneous disease comprising histologically defined subtypes. For therapy selection, precise subtype identification and individualized prognosis are mandatory, but currently ... -
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer.
Alexander, JL; Posma, JM; Scott, A; Poynter, L; Mason, SE; et al. (BMC, 2023-05-08)BACKGROUND AND AIMS: The gut microbiota is implicated in the pathogenesis of colorectal cancer (CRC). We aimed to map the CRC mucosal microbiota and metabolome and define the influence of the tumoral microbiota on oncological ... -
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
Torlot, L; Jarzab, A; Albert, J; Pók-Udvari, Á; Stahler, A; et al. (SPRINGER, 2022-11-19)BACKGROUND: In metastatic colorectal cancer (mCRC), acquired resistance against anti-EGFR targeted monoclonal antibodies, such as cetuximab (CET), was shown to be frequently caused by activating alterations in the RAS genes ... -
Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes.
Somarelli, JA; DeGregori, J; Gerlinger, M; Heng, HH; Marusyk, A; et al. (HUMANA PRESS INC, 2022-07-04)We appear to be faced with 'two truths' in cancer-one of major advances and successes and another one of remaining short-comings and significant challenges. Despite decades of research and substantial progress in treating ... -
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau, D; Kalaitzaki, E; Church, DN; Pandha, H; Tomlinson, I; et al. (ELSEVIER, 2020-01-01)BACKGROUND: 10%-15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease domain mutations, and are characterised by high tumour mutational ... -
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati, S; Martinez, P; Joshi, T; Birkbak, NJ; Santos, CR; et al. (ELSEVIER, 2014-07-19)BACKGROUND: Candidate biomarkers have been identified for clear cell renal cell carcinoma (ccRCC) patients, but most have not been validated. OBJECTIVE: To validate published ccRCC prognostic biomarkers in an independent ... -
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani, S; Barber, LJ; Kleftogiannis, D; Moorcraft, SY; Davidson, M; et al. (OXFORD UNIV PRESS INC, 2018-08-27)BACKGROUND: Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant frequencies. ...